-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 22, 2020 // -- Merck Co) recently presented five-year survival data for the first-line treatment of non-small cell lung cancer (NSCLC) in the key Phase III KEYNOTE-024 trial of the anti-PD-1 therapy Keytruda (Korida, generic name: pembrolizumab, Pabli pearl monoantigen) at the 2020 Virtual Conference of the European Society of Medical Oncology (ESMO).
noteworthy, the results from the KEYNOTE-024 study represent the longest follow-up and first 5-year survival data for immunotherapy in the NSCLC first-line treatment random phase 3 study.
results confirmed that keytruda first-line therapy showed long-lasting long-term survival benefits and long-lasting responses in patients with tumor expression PD-L1 (TPS-50%) and no EGFR or ALC genomic tumor amortization.
Although 66% of patients in the chemotherapy group switched from chemotherapy to subsequent anti-PD-1/PD-L1 therapy, the total survival (OS) rate in the Keytruda group was twice (31.9% vs 16.3%) after five years.
compared to chemotherapy, Keytruda reduced the risk of death by 38% (HR-0.62; 95% CI:0.48-0.81), with a significantly longer total lifetime (medium OS: 26.3 months vs. 13.4 months).
, Keytruda reduced the risk of disease progressity or death by 50% (HR-0.50; 95% CI: 0.39-0.65) compared to chemotherapy, with an extended non-progressed lifetime (medium PF S: 7.7 months vs 5.5 months), improved objective mitigation rate (ORR: 46.1% vs 31.1%), 5 times more mitigation duration (29.1 months vs 6.3 months).
particularly noteworthy is that 81.4 per cent of patients who completed two years of treatment with Keytruda (n-39/154) survived five years and nearly half (46 per cent) did not receive treatment.
data show that patients treated with Keytruda for 2 years can benefit from long-term OS.
patients who completed 2 years of Keytruda treatment, the ORR was 82%.
addition, 12 patients received a second course of treatment.
long follow-up found no new security signals for Keytruda.
31.2% of all patients treated with Keytruda and 53.3% of those treated with chemotherapy had treatment-related adverse events (TRAEs) of level 3-5.
patients treated with Keytruda for 2 years, the rate of TRAE at level 3-5 was 15.4%.
2014, the five-year survival rate for patients with advanced non-small cell lung cancer (NSCLC) in the United States was only 5 percent," said Dr. Martin Reck, M.D., of the Grosshansdorf Lung Clinic at the German Lung Research Center.
31.9 percent of patients treated with Keytruda survived five years later, according to data from the KEYNOTE-024 study released today.
ago, many oncologists, including me, thought it impossible to observe long-term survival outcomes in these metastasis lung cancer patients.
In this study, Keytruda's long-term survival benefits as a single drug are a good example of the significant progress we've made in lung cancer, providing patients with a longer, progress-free life and a chance to live longer. "Keytruda has become the foundational treatment for metastasis lung cancer based on the long-lasting, long-term survival benefits demonstrated in clinical trials," said Dr. Roy Baynes, Senior Vice President and Global Head of Clinical Development, Merca East Research Laboratory,
.
new, first-time five-year survival results from KEYNOTE-024 have increased our understanding of keytruda's important role in lung cancer treatment.
Particularly noteworthy is that five years later, up to 81.4 percent of patients who received Keytruda's two-year treatment were still alive, and nearly half were still untreated, an encouraging new precedent in the treatment of first-line metastassic non-small cell lung cancer.
we thank patients and healthcare providers in this and other trials for their important role in these studies and advancing cancer care.
Origin: First-Line Treatment With Merck's KEYTRUDA® Doubled-Year Survival Rate (31.9%) Versus 40 (16.3%) in Some Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS -50%)